SCHEMBL10157930

SCHEMBL10157930

CCc1ccc(CCF)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.64
TP53 P04637 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
LMNA P02545 1/20 0.43
CYP2A6 P11509 2/20 0.42
LPL P06858 1/20 0.42
LIPG Q9Y5X9 1/20 0.42
ALDH1A1 P00352 1/20 0.41
CA2 P00918 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
ATM Q13315 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.39
PLAU P00749 1/20 0.38
HTR2A P28223 1/20 0.38
GPR84 Q9NQS5 1/20 0.38
TRPA1 O75762 1/20 0.37
PLK1 P53350 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149729 0.85 TAAR1 (0.48) TAAR1TP53L3MBTL1CYP2A6ALDH1A1
SCHEMBL10532365 0.84 LOXL2 (0.52) TAAR1TP53L3MBTL1LMNAALDH1A1
SCHEMBL6546733 0.82 TAAR1 (0.68) TAAR1TP53L3MBTL1LMNACYP2A6
SCHEMBL8728058 0.79 HTR2A (0.56) TP53LMNALPLLIPGALDH1A1
SCHEMBL7902591 0.79 TAAR1 (0.52) TAAR1L3MBTL1ALDH1A1TSHRHTR2A
SCHEMBL36295 0.78 TP53 (0.67) TAAR1TP53L3MBTL1LMNACYP2A6
SCHEMBL4037603 0.78 TAAR1 (0.64) TAAR1L3MBTL1CYP2A6ALDH1A1TDP1
SCHEMBL4920 0.78 TAAR1 (1.00) TAAR1L3MBTL1CYP2A6ALDH1A1TDP1
SCHEMBL9553164 0.77 MAOB (0.52) TAAR1
SCHEMBL11154258 0.77 TAAR1 (0.62) TAAR1TP53L3MBTL1CYP2A6LPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140296228-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION GILEAD SCIENCES, INC. (US) 2014-10-02 US disclosed
EP-2220046-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION GILEAD SCIENCES INC (US) 2014-06-18 EP disclosed
EP-2220076-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INT (DE) 2012-01-18 EP disclosed
EP-2019825-B9 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INT (DE) 2011-01-26 EP disclosed
EP-2019825-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INT (DE) 2010-09-01 EP disclosed
WO-2009062285-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 WO disclosed
WO-2009062289-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 WO disclosed
WO-2009062308-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-22 WO disclosed
WO-2007131350-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296228-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION RTF2, REV1, POLR1E TAAR1 4037/4885TP53 1490/4885L3MBTL1 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.